A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant

[1]  M. Fricová,et al.  Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas. , 2003, Neoplasma.

[2]  L. Douay.  Experimental culture conditions are critical for ex vivo expansion of hematopoietic cells. , 2001, Journal of hematotherapy & stem cell research.

[3]  E. Deconinck,et al.  Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study , 2000, Bone Marrow Transplantation.

[4]  D. Blaise,et al.  Rescue of haemopoiesis by a combination of growth factors including stem-cell factor , 2000, The Lancet.

[5]  H. Weinstein,et al.  The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. , 2000, The oncologist.

[6]  J. Friedberg,et al.  High-dose therapy for follicular lymphoma. , 2000, Oncology.

[7]  T. Lister,et al.  High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Heimfeld,et al.  Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation , 1999 .

[9]  L. Fouillard,et al.  In vivo expansion of reinfused autologous peripheral blood stem cells after a myeloablative regimen, as an alternative to ex vivoexpansion pretransplantation: an intriguing observation in a patient autografted twice , 1999, Bone Marrow Transplantation.

[10]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[11]  J. Vávrová,et al.  The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients. , 1999, Neoplasma.

[12]  M. Labopin,et al.  Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Guerriero,et al.  Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. , 1998, Blood.

[14]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[15]  P. Gaulard,et al.  Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Colombat,et al.  Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Weisenburger,et al.  Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[19]  M. Cazzola,et al.  Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation. , 1994, Bone marrow transplantation.

[20]  S. Lesage,et al.  Administration of three cytokines instead of bone marrow transplantation in an HIV+ patient with high‐grade lymphoma , 1994, European journal of haematology.

[21]  G. Scambia,et al.  In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. , 1994, Bone marrow transplantation.

[22]  F. Locatelli,et al.  Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. , 1994, Bone marrow transplantation.

[23]  J. Armitage,et al.  High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Gribben,et al.  Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. , 1993, Blood.

[25]  L. Fouillard,et al.  GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen , 1991, The Lancet.

[26]  L. Fouillard,et al.  RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR PLUS THE BEAM REGIMEN INSTEAD OF AUTOLOGOUS BONE MARROW TRANSPLANTATION , 1989, The Lancet.

[27]  W. Lorenz.  Attitudes to controlled clinical trials. , 1982, Lancet.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .